Antidote: Provenge

Share this article:
I spend most of my time in this column defending drugs that have been wrongly maligned in the media. Readers know that I am a believer in our best technologies and the options they give. Targeted therapies are expensive, but the wave of the future is clearly genetic and protein modulation, diseases predicted and prevented, and tailored personalized treatments. Immunotherapy—where the immune system is trained to attack invaders is a new front that has led to the development of the vaccine against advanced prostate cancer, known as Provenge.
Even though Provenge has only managed to extend life for three or four months and is quite expensive, it is an exciting new treatment that is the first of its kind to be FDA approved.

I do not need to defend Provenge from media attacks; it has been properly praised as a medical advance by the media. In fact, I don't intend to criticize the media at all this month. But, I would like to do an about face and criticize a drug company.

I want to go on record here and say that I am just appalled at the April FDA report that looked at conditions in the McNeil plant in Pennsylvania, leading to the withdrawal from the market of 43 products for children, including Tylenol, Motrin, Zyrtec, and Benedryl. On the whole they are probably still quite safe, but our children are more sensitive to medications than we are. As the author of a book of how the media and public are prone to overreact to these reports I would be the first to tell you if I thought the attacks on McNeil were overreactions.    

Marc Siegel, MD, is an internist and professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?